| PMID | Proteins | Year | Title |
|---|---|---|---|
| PMID:21331359 | 10 | 2011 | TP53 mutations in nonsmall cell lung cancer. |
| PMID:36290859 | 12 | 2022 | TP53 Mutation Mapping in Advanced Non-Small Cell Lung Cancer: A Real-World Retrospective Cohort Study. |
| PMID:32545367 | 40 | 2020 | TP53 Status, Patient Sex, and the Immune Response as Determinants of Lung Cancer Patient Survival. |
| PMID:36429016 | 40 | 2022 | A Novel TP53 Gene Mutation Sustains Non-Small Cell Lung Cancer through Mitophagy. |
| PMID:35577980 | 27 | 2022 | TP53, CDKN2AP16, and NFE2L2NRF2 regulate the incidence of pure- and combined-small cell lung cancer in mice. |
| PMID:37930190 | 15 | 2023 | Pathogenic germline variants in BRCA1 and TP53 increase lung cancer risk in Chinese. |
| PMID:33673859 | 21 | 2021 | TP53 drives abscopal effect by secretion of senescence-associated molecular signals in non-small cell lung cancer. |
| PMID:35444951 | 29 | 2022 | TP53 Co-Mutations in Advanced EGFR-Mutated Non-Small Cell Lung Cancer: Prognosis and Therapeutic Strategy for Cancer Therapy. |
| PMID:32694238 | 11 | 2020 | TP53 somatic mutations are associated with poor survival in non-small cell lung cancer patients who undergo immunotherapy. |
| PMID:34603310 | 23 | 2021 | TP53 Mutation Status and Biopsy Lesion Type Determine the Immunotherapeutic Stratification in Non-Small-Cell Lung Cancer. |
| PMID:35340160 | 16 | 2022 | [Research Advances of EGFR-TP53 Co-mutation in Advanced Non-small Cell Lung Cancer]. |
| PMID:35779323 | 12 | 2022 | Prognosis of ALK-rearranged non-small-cell lung cancer patients carrying TP53 mutations. |
| PMID:38439876 | 12 | 2024 | TP53 mitigates cisplatin resistance in non-small cell lung cancer by mediating the effects of resistant cell-derived exosome mir-424-5p. |
| PMID:35351459 | 15 | 2022 | TP53 common variants and interaction with PPP1R13L and CD3EAP SNPs and lung cancer risk and smoking behavior in a Chinese population. |
| PMID:34659550 | 14 | 2021 | MIR-4507 Targets TP53 to Facilitate the Malignant Progression of Non-small-cell Lung Cancer. |
| PMID:35280362 | 19 | 2022 | Genomic landscape and prognosis of patients with TP53-mutated non-small cell lung cancer. |
| PMID:30048458 | 13 | 2018 | Distribution of KRAS, DDR2, and TP53 gene mutations in lung cancer: An analysis of Iranian patients. |
| PMID:36918558 | 28 | 2023 | Tp53 haploinsufficiency is involved in hotspot mutations and cytoskeletal remodeling in gefitinib-induced drug-resistant EGFR(L858R)-lung cancer mice. |
| PMID:33968785 | 19 | 2021 | TP53-Activated lncRNA GHRLOS Regulates Cell Proliferation, Invasion, and Apoptosis of Non-Small Cell Lung Cancer by Modulating the miR-346APC Axis. |
| PMID:30165392 | 10 | 2018 | Impact of TP53 mutation status on systemic treatment outcome in ALK-rearranged non-small-cell lung cancer. |
| PMID:36510487 | 6 | 2022 | Quantitative Analysis of TP53-Related Lung Cancer Based on Radiomics. |
| PMID:30054425 | 16 | 2018 | A regulatory circuitry comprising TP53, miR-29 family, and SETDB1 in non-small cell lung cancer. |
| PMID:30843662 | 10 | 2019 | Concomitant TP53 mutations with response to crizotinib treatment in patients with ALK-rearranged non-small-cell lung cancer. |
| PMID:32770960 | 13 | 2020 | The oncogenic potential of a mutant TP53 gene explored in two spontaneous lung cancer mice models. |
| PMID:36864384 | 18 | 2023 | Optimal therapy for concomitant EGFR and TP53 mutated non-small cell lung cancer: a real-world study. |
| PMID:35267450 | 22 | 2022 | The Role of TP53 Mutations in EGFR-Mutated Non-Small-Cell Lung Cancer: Clinical Significance and Implications for Therapy. |
| PMID:31452792 | 11 | 2019 | Mutations in exon 8 of TP53 are associated with shorter survival in patients with advanced lung cancer. |
| PMID:34812534 | 21 | 2022 | Expression and prognostic significance of m6A-related genes in TP53-mutant non-small-cell lung cancer. |
| PMID:27242894 | 8 | 2016 | TP53 Mutation Spectrum in Smokers and Never Smoking Lung Cancer Patients. |
| PMID:37823008 | 10 | 2023 | Correlation Analysis of the TP53 Mutation With Clinical Characteristics in the Prognosis of Non-Small Cell Lung Cancer. |
| PMID:29568386 | 14 | 2018 | Correlation of MET gene amplification and TP53 mutation with PD-L1 expression in non-small cell lung cancer. |
| PMID:36583000 | 19 | 2022 | Case report: TP53 and RB1 loss may facilitate the transformation from lung adenocarcinoma to small cell lung cancer by expressing neuroendocrine markers. |
| PMID:32685741 | 23 | 2020 | Detection of somatic TP53 mutation in surgically resected small-cell lung cancer by targeted exome sequencing: association with longer relapse-free survival. |
| PMID:38394494 | 9 | 2024 | Efficacy of immune checkpoint inhibitors in SMARCA4-deficient and TP53 mutant undifferentiated lung cancer. |
| PMID:29217530 | 14 | 2018 | The Impact of Smoking and TP53 Mutations in Lung Adenocarcinoma Patients with Targetable Mutations-The Lung Cancer Mutation Consortium (LCMC2). |
| PMID:30279957 | 16 | 2018 | Outcome analysis of Phase I trial patients with metastatic KRAS andor TP53 mutant non-small cell lung cancer. |
| PMID:33613692 | 14 | 2021 | Lorlatinib in pretreated ALK- or ROS1-positive lung cancer and impact of TP53 co-mutations: results from the German early access program. |
| PMID:37894716 | 15 | 2023 | The Clinical and Molecular Profile of Lung Cancer Patients Harboring the TP53 R337H Germline Variant in a Brazilian Cancer Center: The Possible Mechanism of Carcinogenesis. |
| PMID:31619231 | 18 | 2019 | Co-mutations of TP53 and KRAS serve as potential biomarkers for immune checkpoint blockade in squamous-cell non-small cell lung cancer: a case report. |
| PMID:32299384 | 21 | 2020 | Prognostic value of TP53 concurrent mutations for EGFR- TKIs and ALK-TKIs based targeted therapy in advanced non-small cell lung cancer: a meta-analysis. |
| PMID:34164277 | 10 | 2021 | Complete disease remission in a TP53 and KRAS co-mutated brain oligometastatic lung cancer patient after immuno-chemotherapy and surgical resection: a case report. |
| PMID:26011298 | 13 | 2015 | TP53 transcription factor for the NEDD9HEF1Cas-L gene: potential targets in Non-Small Cell Lung Cancer treatment. |
| PMID:30196239 | 20 | 2018 | Short-Term Responders of Non-Small Cell Lung Cancer Patients to EGFR Tyrosine Kinase Inhibitors Display High Prevalence of TP53 Mutations and Primary Resistance Mechanisms. |
| PMID:36713848 | 16 | 2023 | Case Report: Chemotherapy-free treatment with camrelizumab and anlotinib for elderly patients with KRAS and TP53 mutated advanced lung cancer. |
| PMID:31711466 | 10 | 2019 | Technical advance in targeted NGS analysis enables identification of lung cancer risk-associated low frequency TP53, PIK3CA, and BRAF mutations in airway epithelial cells. |
| PMID:32782541 | 14 | 2020 | miR129-1 regulates protein phosphatase 1D protein expression under hypoxic conditions in non-small cell lung cancer cells harboring a TP53 mutation. |
| PMID:36440695 | 19 | 2023 | Mutation patterns and evolutionary action score of TP53 enable identification of a patient population with poor prognosis in advanced non-small cell lung cancer. |
| PMID:38900156 | 3 | 2024 | Mutant TP53 promotes invasion of lung cancer cells by regulating desmoglein 3. |
| PMID:37712717 | 10 | 2023 | The possibility of mutations of RAS signaling genes andor TP53 in combination as a negative prognostic impact on pathological stage I non-small cell lung cancer. |
| PMID:28978051 | 19 | 2017 | Mutational status of TP53 defines the efficacy of Wee1 inhibitor AZD1775 in KRAS-mutant non-small cell lung cancer. |
| PMID:35256783 | 3 | 2022 | TP53 mutations upregulate RCP expression via Sp13 to drive lung cancer progression. |
| PMID:34031188 | 4 | 2021 | TP53 Null Mutations Identify Lung Cancer Cell Lines with Highest Sensitivity to the Nontaxane Microtubule Inhibitor Eribulin. |
| PMID:35693277 | 21 | 2022 | Triptolide promotes degradation of the unfolded gain-of-function Tp53(R175HY220C) mutant protein by initiating heat shock protein 70 transcription in non-small cell lung cancer. |
| PMID:36351964 | 6 | 2022 | Genomic analysis of early-stage lung cancer reveals a role for TP53 mutations in distant metastasis. |
| PMID:29618932 | 7 | 2018 | miR-1269 promotes cell survival and proliferation by targeting tp53 and caspase-9 in lung cancer. |
| PMID:29423041 | 7 | 2018 | Individual and combined effect of TP53, MDM2, MDM4, MTHFR, CCR5, and CASP8 gene polymorphisms in lung cancer. |
| PMID:33959694 | 7 | 2020 | The cell cycle regulatory gene polymorphisms TP53 (rs1042522) and MDM2 (rs2279744) in lung cancer: a meta-analysis. |
| PMID:37236507 | 4 | 2023 | Mutation of TP53 Confers Ferroptosis Resistance in Lung Cancer Through the FOXM1MEF2C Axis. |
| PMID:35190375 | 12 | 2022 | Clinical efficacy of atezolizumab plus bevacizumab and chemotherapy in KRAS-mutated non-small cell lung cancer with STK11, KEAP1, or TP53 comutations: subgroup results from the phase III IMpower150 trial. |
| PMID:36320308 | 7 | 2022 | Mutation and up-regulation of TP53 in ovine pulmonary adenocarcinoma lung cells as a model of human lung cancer. |
| PMID:32780611 | 8 | 2020 | Reduction of pericardial effusion in advanced non-small cell lung cancer patients with KRAS, TP53, and MET mutation treated with nivolumab. |
| PMID:32034480 | 5 | 2020 | High Expression of CARM1 Inhibits Lung Cancer Progression by Targeting TP53 by Regulating CTNNB1. |
| PMID:29956783 | 9 | 2018 | Next-generation sequencing-based detection of EGFR, KRAS, BRAF, NRAS, PIK3CA, Her-2 and TP53 mutations in patients with non-small cell lung cancer. |
| PMID:36810856 | 9 | 2023 | Transformation or tumor heterogeneity: Mutations in EGFR, SOX2, TP53, and RB1 persist in the histological rapid conversion from lung adenocarcinoma to small-cell lung cancer. |
| PMID:33569305 | 27 | 2021 | Role of next generation sequencing-based liquid biopsy in advanced non-small cell lung cancer patients treated with immune checkpoint inhibitors: impact of STK11, KRAS and TP53 mutations and co-mutations on outcome. |
| PMID:32194690 | 6 | 2020 | MicroRNA-107 may regulate lung cancer cell proliferation and apoptosis by targeting TP53 regulated inhibitor of apoptosis 1. |
| PMID:31281482 | 7 | 2019 | Expression of WDR79 is associated with TP53 mutation and poor prognosis in surgically resected non-small cell lung cancer. |
| PMID:30784913 | 7 | 2019 | Integrated analysis of the prognostic value of TP53 dependent etoposide-induced gene 24 in non-small cell lung cancer. |
| PMID:20436704 | 5 | 2010 | TP53 mutations in Korean patients with non-small cell lung cancer. |
| PMID:32753898 | 5 | 2020 | Association of TP53 Mutations with Response to Anlotinib Treatment in Advanced Non-Small Cell Lung Cancer. |
| PMID:24760004 | 13 | 2014 | Frequent mutations in EGFR, KRAS and TP53 genes in human lung cancer tumors detected by ion torrent DNA sequencing. |
| PMID:38330261 | 7 | 2024 | Influence of TP53 Comutation on the Tumor Immune Microenvironment and Clinical Outcomes With Immune Checkpoint Inhibitors in STK11-Mutant Non-Small-Cell Lung Cancer. |
| PMID:28638459 | 16 | 2017 | Towards Prognostic Profiling of Non-Small Cell Lung Cancer: New Perspectives on the Relevance of Polo-Like Kinase 1 Expression, the TP53 Mutation Status and Hypoxia. |
| PMID:32953734 | 7 | 2020 | Interaction between common variants of MDM2 and PPP1R13L and CD3EAP and TP53 SNPs in relation to lung cancer risk among Chinese. |
| PMID:37612638 | 2 | 2023 | TP53 mutation prevalence in normal airway epithelium as a biomarker for lung cancer risk. |
| PMID:38431700 | 4 | 2024 | TP53 gain-of-function mutations promote osimertinib resistance via TNF-alpha-NF-kappaB signaling in EGFR-mutated lung cancer. |
| PMID:23364678 | 10 | 2013 | Poly(beta-amino ester) nanoparticle delivery of TP53 has activity against small cell lung cancer in vitro and in vivo. |
| PMID:36800249 | 8 | 2023 | Successful neoadjuvant treatment of EGFR exon 19 deletion combined with TP53 mutation in non-small cell lung cancer using aumolertinib after osimertinib-induced myocardial damage: a case report and literature review. |
| PMID:38071953 | 4 | 2024 | Higher TP53 somatic mutation prevalence from liquid biopsy analysis in ever smoker non-small-cell lung cancer patients. |
| PMID:30766968 | 4 | 2018 | Influence of TP53 Mutation on Survival in Patients With Advanced EGFR-Mutant Non-Small-Cell Lung Cancer. |
| PMID:36551611 | 3 | 2022 | TP53 Co-Mutation Status Association with Clinical Outcomes in Patients with EGFR-Mutant Non-Small Cell Lung Cancer. |
| PMID:30265285 | 2 | 2018 | TP53 mutations are predictive and prognostic when co-occurring with ALK rearrangements in lung cancer. |
| PMID:28425245 | 7 | 2017 | Xenobioticdrug metabolizing enzyme and TP53 polymorphisms and clinical outcome in advanced nonsmall cell lung cancer patients. |
| PMID:36522487 | 3 | 2023 | Long non-coding RNA TILR constitutively represses TP53 and apoptosis in lung cancer. |
| PMID:31428721 | 6 | 2019 | Impact of KRAS and TP53 Co-Mutations on Outcomes After First-Line Systemic Therapy Among Patients With STK11-Mutated Advanced Non-Small-Cell Lung Cancer. |
| PMID:38237562 | 3 | 2024 | Coexpression of TP53, BIM, and PTEN Enhances the Therapeutic Efficacy of Non-Small-Cell Lung Cancer. |
| PMID:30669647 | 4 | 2019 | Detection of TP53 Mutations in Tissue or Liquid Rebiopsies at Progression Identifies ALK+ Lung Cancer Patients with Poor Survival. |
| PMID:31100334 | 3 | 2019 | TP53, EGFR and PIK3CA gene variations observed as prominent biomarkers in breast and lung cancer by plasma cell-free DNA genomic testing. |
| PMID:36002660 | 3 | 2022 | Correction: TP53, CDKN2AP16, and NFE2L2NRF2 regulate the incidence of pure- and combined-small cell lung cancer in mice. |
| PMID:32818633 | 3 | 2020 | Evolutionary genomics of mammalian lung cancer genes reveals signatures of positive selection in APC, RB1 and TP53. |
| PMID:37223539 | 6 | 2023 | A focused transcriptomic analysis of the TP53-regulated genes identifies the GPI-anchored molecule-like protein (GML) as a favorable prognostic predictor of lung cancer. |
| PMID:30591959 | 7 | 2019 | Randomized-controlled phase II trial of salvage chemotherapy after immunization with a TP53-transfected dendritic cell-based vaccine (Ad.p53-DC) in patients with recurrent small cell lung cancer. |
| PMID:21559393 | 23 | 2011 | Molecular mode of action and role of TP53 in the sensitivity to the novel epothilone sagopilone (ZK-EPO) in A549 non-small cell lung cancer cells. |
| PMID:35226388 | 4 | 2021 | Prognostic effect of coexisting TP53 and ZFHX3 mutations in non-small cell lung cancer patients treated with immune checkpoint inhibitors. |
| PMID:38776912 | 4 | 2024 | Targeting WEE1 enhances the antitumor effect of KRAS-mutated non-small cell lung cancer harboring TP53 mutations. |
| PMID:34088750 | 2 | 2021 | The Association between Polluted Neighborhoods and TP53-Mutated Non-Small Cell Lung Cancer. |
| PMID:31516572 | 5 | 2019 | Non-invasive detection of EGFR and TP53 mutations through the combination of plasma, urine and sputum in advanced non-small cell lung cancer. |
| PMID:29854570 | 3 | 2018 | Epidermal Growth Factor Receptor-mutated Lung Cancer as the Initial Manifestation of Germline TP53 Mutation Associated Cancer. |
| PMID:30885352 | 5 | 2019 | Mutation patterns in a population-based non-small cell lung cancer cohort and prognostic impact of concomitant mutations in KRAS and TP53 or STK11. |
| PMID:35598358 | 3 | 2022 | The impact of TP53 co-mutations and immunologic microenvironment on outcome of lung cancer with EGFR exon 20 insertions. |
| PMID:35200387 | 4 | 2022 | Detection and Quantification of Tp53 and p53-Anti-p53 Autoantibody Immune Complex: Promising Biomarkers in Early Stage Lung Cancer Diagnosis. |
| PMID:35242623 | 3 | 2022 | TP53 co-mutations as an independent prognostic factor in 2nd and further line therapy-EGFR mutated non-small cell lung cancer IV patients treated with osimertinib. |
| PMID:32272775 | 2 | 2020 | Concomitant TP53 Mutation Confers Worse Prognosis in EGFR-Mutated Non-Small Cell Lung Cancer Patients Treated with TKIs. |
| PMID:38271745 | 2 | 2024 | First-line immunotherapy for lung cancer with MET exon 14 skipping and the relevance of TP53 mutations. |
| PMID:33920322 | 5 | 2021 | Simultaneous Identification of EGFR,KRAS,ERBB2, and TP53 Mutations in Patients with Non-Small Cell Lung Cancer by Machine Learning-Derived Three-Dimensional Radiomics. |
| PMID:32592343 | 3 | 2020 | Association of TP53 Codon 72 Arg>Pro Polymorphism with Breast and Lung Cancer Risk in the South Asian Population: A Meta-Analysis. |
| PMID:37042869 | 3 | 2023 | Concomitant TP53 mutation in early-stage resected EGFR-mutated non-small cell lung cancer: a narrative approach in a genetically admixed Brazilian cohort. |
| PMID:30867754 | 10 | 2019 | Prognostic value of KRASTP53PIK3CA in non-small cell lung cancer. |
| PMID:35216740 | 2 | 2022 | KEAP1 and TP53 Mutations in Lung Cancer: More Is Better. Reply to: Survival Analysis of TP53 Co-Mutations Should Be Interpreted More Cautiously. |
| PMID:31097096 | 3 | 2019 | Association of TP53 mutations with response and longer survival under immune checkpoint inhibitors in advanced non-small-cell lung cancer. |
| PMID:27182622 | 2 | 2017 | KRAS and TP53 mutations in bronchoscopy samples from former lung cancer patients. |
| PMID:37787291 | 4 | 2023 | The XRCC1 and TP53 gene polymorphisms are associated with advanced-stage disease and early distant metastasis at diagnosis in non-small cell lung cancer. |
| PMID:30798634 | 2 | 2019 | The prognostic impact of TP53 comutation in EGFR mutant lung cancer patients: a systematic review and meta-analysis. |
| PMID:28033105 | 4 | 2016 | Association between the TP53 and CYP2E1*5B gene polymorphisms and non-small cell lung cancer. |
| PMID:38872053 | 3 | 2024 | The clinical features and prognostic implications of the co-mutated TP53 gene in advanced non-small cell lung cancer. |
| PMID:36833388 | 4 | 2023 | Association between Polymorphism of Genes IL-1A, NFKB1, PAR1, TP53, and UCP2 and Susceptibility to Non-Small Cell Lung Cancer in the Brazilian Amazon. |
| PMID:39066480 | 2 | 2024 | CRISPR-mediated ablation of TP53 and EGFR mutations enhances gefitinib sensitivity and anti-tumor efficacy in lung cancer. |
| PMID:30770327 | 2 | 2019 | Effect of Coexisting KRAS and TP53 Mutations in Patients Treated With Chemotherapy for Non-small-cell Lung Cancer. |
| PMID:37754531 | 4 | 2023 | Concordance of Abundance for Mutational EGFR and Co-Mutational TP53 with Efficacy of EGFR-TKI Treatment in Metastatic Patients with Non-Small-Cell Lung Cancer. |
| PMID:38457554 | 2 | 2024 | High expression of KIFC1 is a poor prognostic biomarker and correlates with TP53 mutation in lung cancer. |
| PMID:28101350 | 3 | 2016 | TP53 mutation is associated with a poor clinical outcome for non-small cell lung cancer: Evidence from a meta-analysis. |
| PMID:26689115 | 2 | 2016 | TP53 and MDM2 genetic alterations in non-small cell lung cancer: Evaluating their prognostic and predictive value. |
| PMID:15564288 | 2 | 2005 | Polymorphisms in XPD and TP53 and mutation in human lung cancer. |
| PMID:27900000 | 3 | 2016 | Involvement of TP53 and TP16 expression in human papillomavirus-associated non-small cell lung cancer. |
| PMID:34967559 | 2 | 2021 | Effect of XPD and TP53 Gene Polymorphisms on the Risk of Platinum-Based Chemotherapy Induced Toxicity in Bangladeshi Lung Cancer Patients. |
| PMID:33317922 | 3 | 2021 | Predictive and Prognostic Potential of TP53 in Patients With Advanced Non-Small-Cell Lung Cancer Treated With EGFR-TKI: Analysis of a Phase III Randomized Clinical Trial (CTONG 0901). |
| PMID:33194065 | 2 | 2020 | Molecular diagnosis and clinical outcome of a lung cancer patient with TP53-E285K mutated Li-Fraumeni syndrome harboring a somatic EGFR-KDD mutation. |
| PMID:38832214 | 2 | 2024 | Influence of TP53 mutation on efficacy and survival in advanced EGFR-mutant non-small cell lung cancer patients treated with third-generation EGFR tyrosine kinase inhibitors. |
| PMID:22065914 | 4 | 2011 | Polymorphisms in apoptosis-related genes and TP53 mutations in non-small cell lung cancer. |
| PMID:26780934 | 5 | 2016 | Mutations in TP53 increase the risk of SOX2 copy number alterations and silencing of TP53 reduces SOX2 expression in non-small cell lung cancer. |
| PMID:19661141 | 7 | 2009 | Increased tissue factor expression is associated with reduced survival in non-small cell lung cancer and with mutations of TP53 and PTEN. |
| PMID:30089598 | 2 | 2018 | The prognostic value of TP53 and its correlation with EGFR mutation in advanced non-small cell lung cancer, an analysis based on cBioPortal data base. |
| PMID:32023774 | 2 | 2020 | [The influence of TP53 mutation on the therapeutic effect of EGFR tyrosine kinase inhibitor and prognosis of EGFR mutant non-small cell lung cancer patients]. |
| PMID:36773668 | 2 | 2023 | Meta-analysis of the prognostic impact of TP53 co-mutations in EGFR-mutant advanced non-small-cell lung cancer treated with tyrosine kinase inhibitors. |
| PMID:20372852 | 3 | 2010 | Cigarette smoking, TP53 Arg72Pro, TP53BP1 Asp353Glu and the risk of lung cancer in a Japanese population. |
| PMID:28838393 | 3 | 2017 | Prognostic and predictive effects of TP53 co-mutation in patients with EGFR-mutated non-small cell lung cancer (NSCLC). |
| PMID:22267755 | 3 | 2012 | Prognostic value of TP53, KRAS and EGFR mutations in nonsmall cell lung cancer: the EUELC cohort. |
| PMID:33198130 | 11 | 2020 | The Polemic Diagnostic Role of TP53 Mutations in Liquid Biopsies from Breast, Colon and Lung Cancers. |
| PMID:12169206 | 4 | 2002 | MYCL1, FHIT, SPARC, p16(INK4) and TP53 genes associated to lung cancer in idiopathic pulmonary fibrosis. |
| PMID:23435014 | 4 | 2013 | Differential mutation profiles and similar intronic TP53 polymorphisms in asbestos-related lung cancer and pleural mesothelioma. |
| PMID:36809053 | 2 | 2023 | Loss of Rb1 Associated With the Onset of Acquired Resistance to Trastuzumab Deruxtecan in TP53-HER2-Mutated Non-Small-Cell Lung Cancer: Case Series. |
| PMID:21129811 | 4 | 2011 | Associations between polymorphisms in DNA repair genes and TP53 mutations in non-small cell lung cancer. |
| PMID:29588850 | 14 | 2018 | TP53TG1 enhances cisplatin sensitivity of non-small cell lung cancer cells through regulating miR-18aPTEN axis. |
| PMID:37693094 | 33 | 2023 | Ze-Qi decoction inhibits non-small cell lung cancer growth and metastasis by modulating the PI3KAktp53 signaling pathway. |
| PMID:38093368 | 27 | 2023 | Nutlin-3a induces KRAS mutantp53 wild type lung cancer specific methuosis-like cell death that is dependent on GFPT2. |
| PMID:37038985 | 2 | 2023 | Efficacy of immunotherapy as second-line or later-line therapy and prognostic significance of KRAS or TP53 mutations in advanced non-small cell lung cancer patients. |
| PMID:25596702 | 4 | 2015 | Prognostic value of ERCC1, ERCC2, XRCC1, and TP53 single nucleotide polymorphisms in patients with early-stage non-small cell lung cancer. |
| PMID:31228622 | 47 | 2019 | Concurrent RB1 and TP53 Alterations Define a Subset of EGFR-Mutant Lung Cancers at risk for Histologic Transformation and Inferior Clinical Outcomes. |
| PMID:27646734 | 2 | 2017 | Multiregion sequencing reveals the intratumor heterogeneity of driver mutations in TP53-driven non-small cell lung cancer. |
| PMID:12409262 | 4 | 2002 | Adenovirus-mediated mda-7 gene expression radiosensitizes non-small cell lung cancer cells via TP53-independent mechanisms. |
| PMID:34718338 | 29 | 2021 | MicroRNA-106a regulates autophagy-related cell death and EMT by targeting TP53INP1 in lung cancer with bone metastasis. |
| PMID:10557071 | 3 | 1999 | Inactivation of the INK4AARF locus frequently coexists with TP53 mutations in non-small cell lung cancer. |
| PMID:35887201 | 28 | 2022 | Cytochrome P450 27C1 Level Dictates Lung Cancer Tumorigenicity and Sensitivity towards Multiple Anticancer Agents and Its Potential Interplay with the IGF-1RAktp53 Signaling Pathway. |
| PMID:22154617 | 4 | 2011 | Effect of CYP1A1 MSPI polymorphism on the relationship between TP53 mutation and CDKN2A hypermethylation in non-small cell lung cancer. |
| PMID:15609317 | 3 | 2005 | Association of amino acid substitution polymorphisms in DNA repair genes TP53, POLI, REV1 and LIG4 with lung cancer risk. |
| PMID:12875622 | 2 | 2003 | Different risk relations with smoking for non-small-cell lung cancer: comparison of TP53 and TP73 genotypes. |
| PMID:37873210 | 28 | 2023 | FORMATION OF MALIGNANT, METASTATIC SMALL CELL LUNG CANCERS THROUGH OVERPRODUCTION OF cMYC PROTEIN IN TP53 AND RB1 DEPLETED PULMONARY NEUROENDOCRINE CELLS DERIVED FROM HUMAN EMBRYONIC STEM CELLS. |
| PMID:11677115 | 3 | 2001 | A role for c-myc in DNA damage-induced apoptosis in a human TP53-mutant small-cell lung cancer cell line. |
| PMID:28453411 | 3 | 2017 | Pooled Analysis of the Prognostic and Predictive Effects of TP53 Comutation Status Combined With KRAS or EGFR Mutation in Early-Stage Resected Non-Small-Cell Lung Cancer in Four Trials of Adjuvant Chemotherapy. |
| PMID:16287156 | 2 | 2006 | Genetic polymorphisms in cell cycle regulatory genes MDM2 and TP53 are associated with susceptibility to lung cancer. |
| PMID:25842826 | 2 | 2014 | [Association of polymorphic markers Arg72Pro of TP53 and T309g of MDM2 genes with non small cell lung cancer in Russians of Moscow region]. |
| PMID:24732641 | 2 | 2014 | MDM2 rs2279744 and TP53 rs1042522 polymorphisms associated with etoposide- and cisplatin-induced grade IIIIV neutropenia in Chinese extensive-stage small-cell lung cancer patients. |
| PMID:12071807 | 2 | 2002 | 7-Hydroxystaurosporine (UCN-01) preferentially sensitizes cells with a disrupted TP53 to gamma radiation in lung cancer cell lines. |
| PMID:23742673 | 2 | 2013 | Association between a rare novel TP53 variant (rs78378222) and melanoma, squamous cell carcinoma of head and neck and lung cancer susceptibility in non-Hispanic Whites. |
| PMID:18296270 | 2 | 2008 | Immunoexpression of P16INK4a, Rb and TP53 proteins in bronchiolar columnar cell dysplasia (BCCD) in lungs resected due to primary non-small cell lung cancer. |
| PMID:24374662 | 2 | 2014 | Association of miR-502-binding site single nucleotide polymorphism in the 3-untranslated region of SET8 and TP53 codon 72 polymorphism with non-small cell lung cancer in Chinese population. |
| PMID:36065989 | 3 | 2022 | Non-small-cell lung cancer patients harboring TP53KRAS co-mutation could benefit from a PD-L1 inhibitor. |
| PMID:28285689 | 6 | 2017 | Mutations in TP53, PIK3CA, PTEN and other genes in EGFR mutated lung cancers: Correlation with clinical outcomes. |
| PMID:31359406 | 4 | 2020 | Radioresistance of KRASTP53-mutated lung cancer can be overcome by radiation dose escalation or EGFR tyrosine kinase inhibition in vivo. |
| PMID:33845248 | 6 | 2021 | A case of dramatic reduction in cancer-associated thrombus following initiation of pembrolizumab in patient with a poor performance status and PD-L1(+) lung adenocarcinoma harboring CCDC6-RET fusion gene and NF1TP53 mutations. |
| PMID:31544704 | 4 | 2019 | The Pharmacogenomics Side-effect of TP53EGFR in Non-small Cell Lung Cancer Accompanied with Atorvastatin Therapy: A Functional Network Analysis. |
| PMID:33416121 | 4 | 2021 | Long non-coding RNA FER1L4 inhibits cell proliferation and promotes cell apoptosis via the PTENAKTp53 signaling pathway in lung cancer. |
| PMID:28479246 | 3 | 2017 | TP53 gene status is a critical determinant of phenotypes induced by ALKBH3 knockdown in non-small cell lung cancers. |
| PMID:39086589 | 5 | 2024 | The Investigation of Quercus Infectoria Gall Aqueous Extract Effect on the Cell Proliferation, Apoptosis and Expression of CCND1, TP53, BCL2 and BAX Genes in Cell Line of Lung, Gastric and Esophageal Cancers. |
| PMID:28499267 | 3 | 2017 | A novel germline TP53 mutation p.Pro190Arg detected in a patient with lung and bilateral breast cancers. |
| PMID:38096950 | 4 | 2024 | Outcome of First-Line Treatment With Pembrolizumab According to KRASTP53 Mutational Status for Nonsquamous Programmed Death-Ligand 1-High (>=50%) NSCLC in the German National Network Genomic Medicine Lung Cancer. |
| PMID:20018398 | 5 | 2010 | PTEN mutations and relationship to EGFR, ERBB2, KRAS, and TP53 mutations in non-small cell lung cancers. |
| PMID:17575133 | 5 | 2007 | Patterns of EGFR, HER2, TP53, and KRAS mutations of p14arf expression in non-small cell lung cancers in relation to smoking history. |
| PMID:15958551 | 3 | 2005 | TP53 and KRAS mutation load and types in lung cancers in relation to tobacco smoke: distinct patterns in never, former, and current smokers. |
| PMID:37007549 | 2 | 2023 | Acquired L718VTP53 co-mutation and discordant molecular pattern between plasmatic and cerebrospinal fluid in a bone and meningeal metastatic L858R+ non-small cell lung cancer: a case report. |
| PMID:22510504 | 2 | 2012 | [Expressions and significance of TIMP-3 and mtp53 in non-small cell lung cancer]. |
| PMID:36503478 | 2 | 2022 | Efficacy and safety analyses of epidermal growth factor receptor tyrosine kinase inhibitors combined with chemotherapy in the treatment of advanced non-small-cell lung cancer with an EGFRTP53 co-mutation. |
| PMID:20198299 | 2 | 2010 | PTENpAktp53 signaling pathway correlates with the radioresponse of non-small cell lung cancer. |
| PMID:18413811 | 3 | 2008 | WTp53 induction does not override MTp53 chemoresistance and radioresistance due to gain-of-function in lung cancer cells. |
| PMID:20929632 | 2 | 1999 | [The clinicopathologic significance of expression of mtp53, p16 and Bcl-2 protein in lung cancer.]. |
| PMID:23664447 | 3 | 2013 | Genetic and epigenetic alterations of the LKB1 gene and their associations with mutations in TP53 and EGFR pathway genes in Korean non-small cell lung cancers. |
| PMID:37877748 | 2 | 2024 | Valproic acid increased the efficacy of EGFR TKIs on EGFRTP53 co-mutated lung cancers and downregulated mutant-p53 levels. |
Last active
September 21, 2024 17:51
-
-
Save donbr/6e91c56a147f7271f091caaccf6400f1 to your computer and use it in GitHub Desktop.
Sign up for free
to join this conversation on GitHub.
Already have an account?
Sign in to comment